VIR logo

VIRVir Biotechnology Inc

$8.61
$0.00
(0.00%)
Today
Closed $8.61
$0.00
(0.00%)
After Hours
Updated: 06:59 PM EDT
EarningsAug 5
Mkt Cap$1.45B
Vol1.4M
56

Bullish Sentiment

How do you feel about VIR?

News
all
press releases
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. We are pleased to welcome Tim to Vir Biotechnologys Board of Directors at a pivotal moment for the company, said Marianne...
Business Wire
News Placeholder
More News
News Placeholder
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now...
Yahoo! Finance: News
News Placeholder
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta...
Business Wire
News Placeholder
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million...
Yahoo! Finance: News
News Placeholder
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares...
Yahoo! Finance: News
News Placeholder
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Key PointsVicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share...
Nasdaq News: Markets
News Placeholder
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. Vir Bio delivered incredible momentum during the...
Business Wire
News Placeholder
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026...
Business Wire
News Placeholder
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the transaction, the...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.